In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
International Journal of Pharmaceutics: X, 2021 Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels ...
Sawittree Sahakijpijarn +7 more
doaj +1 more source
A brief overview of current drug repurposing approaches for COVID-19 management [PDF]
, 2020 This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares +1 more
core +2 more sources
Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters
Pharmaceutics, 2021 Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies +5 more
doaj +1 more source
BMC Infectious Diseases, 2023 Background Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs.
Chuizhe Chen +6 more
doaj +1 more source
Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the Observed Severity of COVID-19? [PDF]
, 2020 Human lungs single cell RNA sequencing data from healthy donors (elderly and young; GEO accession number GSE122960) were analyzed to isolate and specifically study gene expression in alveolar type II cells.
Abouhashem, Ahmed S. +3 more
core +1 more source
Diagnosis and Management of COVID-19 Disease [PDF]
, 2020 SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham +5 more
core +1 more source
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19 [PDF]
, 2022 Remdesivir is the first US Food and Drug Administration (FDA)-approved drug for the treatment of coronavirus disease 2019 (COVID-19). We conducted a retrospective pharmacogenetic study to examine remdesivir-associated liver enzyme elevation among Million
Chanfreau, Catherine +19 more
core +1 more source
Acta Medica Iranica, 2022 Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi +12 more
doaj +1 more source
Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]
, 2020 On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P. +4 more
core +2 more sources